Bale/Doneen Live Chat Session

3/13/2013 5:30-6:30 pm PST

Bradley Bale, MD




Intention of the live chats

- New data and slides
- Discuss "hot" topics
- Case study
- Review upcoming meetings
- Open discussion for remaining




New Studies??!!!: OMG!



Way too many to discuss. Will concentrate on four only.











Periodontal Disease & Treatment Related to Risk of Stroke

- 510,762 PD & 208,674 non-PD pts; divided PD pts into prophylactic rx, intensive rx (subgingival curettage, root planning, periodontal flap or extraction), no rx
- Follow-up ~ 8 yrs.; 15,141 pts developed ischemic stroke
- Adjusted for age, sex and comorbidities (BP, DM, dyslipidemia, AF, CKD, subclinical ASVD) to assess incident risk (IR) of stroke

Lee, Y-L, DDS, et. al. Stroke 2/19/2013; 44: XXX-XXX

DOI: 10.1161/STROKEAHA.111.000076



Periodontal Wellness Reduces Risk of Stroke

IR for PD prophylactic rx was 0.14%/year

IR for non-PD pts. was 0.32%/year

IR for intensive rx was 0.39%/year

IR for no rx was 0.48%/year

Lee, Y-L, DDS, et. al. Stroke 2/19/2013; 44: XXX-XXX DOI: 10.1161/STROKEAHA.111.000076



Periodontal Wellness Reduces Risk of Stroke

 After adjustment for confounders, the dental prophylaxis and intensive treatment groups had a significant lower hazard ratios for stroke than the non-PD group
 HR-0.78 & 0.95 (95% CI 0.75–0.81 & 0.91–0.99)

PD without rx compared to non-PD group

HR-1.15 (95% CI 1.07–1.24)

among the youngest (20-44) age group

HR-2.17 (95% CI 1.64–2.87)

Lee, Y-L, DDS, et. al. Stroke 2/19/2013; 44: XXX-XXX

DOI: 10.1161/STROKEAHA.111.000076



Periodontal Wellness Reduces Risk of Stroke: Conclusions

PD is an important risk factor for ischemic stroke

 PD patients who received treatment have a lower risk of stroke, especially among young subjects

Lee, Y-L, DDS, et. al. Stroke 2/19/2013; 44: XXX-XXX

DOI: 10.1161/STROKEAHA.111.000076



What About Endodontic Disease?







- 101 acute heart attack pts; 76% male; ~63 yo
- Obstructing thrombi and arterial blood analyzed by PCR for oral pathogens

- Bacterial DNA load 16 times greater in the thrombithan the arterial blood sample
- Oral viridans streptococci found in 78% of thrombi; PD pathogens found in 35% of thrombi



- Most frequently found bacterial DNA was from Streptococcus sp. mainly Str. mitis-group (72.3%)
- Most frequently found PD pathogens were:
 Aggregatibacter actinomycetemcomitans (5.9 %)
 and Porphyromonas gingivalis (5.0 %)

- Viridans streptococci traditionally are assumed to be the most important organisms in periapical lesions.
- Oral viridans group streptococci are capable of invading human aortic endothelial cells and triggering the production of inflammatory cytokines and monocyte chemoattractant proteins
- Oral streptococci may initiate or contribute to platelet aggregation in coronaries – clot formation !!

- Bacteremia originating from the oral cavity is common
- Happens following tooth brushing, tooth extraction and root canal treatment
- They are phagocytosed and may be translocated into the atherosclerotic plaque, or may end up in the plaque directly through the endothelium or via vasa vasorum

- 30 pts had panoramic CT imaging
- ~50% showed periapical abscess

 If pt's thrombus was positive for strep viridans DNA, they were 13 times more likely to have a periapical abscess

OR 13.2 (95% CI 2.11 – 82.5) p=0.004



- Electron microscopy performed on 9 thrombi
- Bacteria-like structures detected in all 9; whole bacteria in
 3/9

Immunohistochemistry for substances indicative of bacteria performed in 8 thrombi: CD 14 (bacteria recognition in monocyte/macrophage) and CD68 (inflammation from bacteria)

CD14 and CD68 detected in all 8




Oral Pathogens and Acute Heart Attack: Conclusions

 Dental infection and oral bacteria are associated with the development of acute coronary thrombosis – heart attack!!!

 Dental health and dental care should be one major element in preventing heart attacks!!!

- Bale/Doneen Method Thoughts
- 1) Endodontic infection appears very common in heart attack pts; may trigger up to half of the heart attacks!!
- 2) All patients suffering a heart attack need a thorough oral health exam which includes PD pathogen testing as well as panoramic tomography.
- 3) This evaluation should be performed by an oral medicine specialist
 - 4) This needs to become the standard of care

EDFROG IRA





Laziness: it is a natural occurrence

This happened in the Shamattawa Dump in Manitoba, Canada









What to Consume??















 7,747 high CV risk pts.; 57% female; 55 - 80 yo; end points CV events and death; Mediterranean diet –a) extra virgin olive oil b) extra nuts versus low fat diet; unrestricted caloric diets; halted at 4.8 yrs.

Estruch R et al. N Engl J Med 2013. DOI: 10.1056/NEJMoa1200303



- Inclusion criteria ensuring high CV risk
 - a) type 2 diabetes or
 - b) three or more of the following:
 - 1) smoking
 - 2) hypertension
 - 3) LDL \geq 160 mg/dL
 - 4) HDL ≤ 40 mg/dL
 - 5) BMI ≥ 25
 - 6) +Famhx
 - 7) if HDL \geq 60mg/dL, subtract one



- Exclusion criteria:
 - a) known CVD
 - b) major co-morbid conditions
 - c) inability to follow either diet plan
 - d) drug abusers



Baseline Medications

Mediterranean Diet with EVOO (N = 2543)	Mediterranean Diet with Nuts (N=2454)	Control Diet (N = 2450)	
1236 (48.6)	1223 (49.8)	1216 (49.6)	
534 (21.0)	477 (19.4)	562 (22.9)	
725 (28.5)	710 (28.9)	758 (30.9)	
1039 (40.9)	964 (39.3)	983 (40.1)	
121 (4.8)	145 (5.9)	126 (5.1)	
124 (4.9)	126 (5.1)	134 (5.5)	
768 (30.2)	680 (27.7)	757 (30.9)	P<0.05
475 (18.7)	490 (20.0)	513 (20.9)	
42 (2.8)	35 (2.6)	39 (2.7)	Womei only
8.7±2.0	8.7±2.0	8.4±2.1	
	Diet with EVOO (N = 2543) 1236 (48.6) 534 (21.0) 725 (28.5) 1039 (40.9) 121 (4.8) 124 (4.9) 768 (30.2) 475 (18.7) 42 (2.8)	Diet with EVOO (N = 2543) Diet with Nuts (N = 2454) 1236 (48.6) 1223 (49.8) 534 (21.0) 477 (19.4) 725 (28.5) 710 (28.9) 1039 (40.9) 964 (39.3) 121 (4.8) 124 (4.9) 126 (5.1) 768 (30.2) 680 (27.7) 475 (18.7) 490 (20.0) 42 (2.8) 35 (2.6)	Diet with EVOO (N=2543) Diet with Nuts (N=2454) Control Diet (N=2450) 1236 (48.6) 1223 (49.8) 1216 (49.6) 534 (21.0) 477 (19.4) 562 (22.9) 725 (28.5) 710 (28.9) 758 (30.9) 1039 (40.9) 964 (39.3) 983 (40.1) 121 (4.8) 145 (5.9) 126 (5.1) 124 (4.9) 126 (5.1) 134 (5.5) 768 (30.2) 680 (27.7) 757 (30.9) 475 (18.7) 490 (20.0) 513 (20.9) 42 (2.8) 35 (2.6) 39 (2.7)

Estruch R et al. N Engl J Med 2013. DOI: 10.1056/NEJMoa1200303



Basic Dietary Advice

Food	Goal
Mediterranean diet	
Recommended	
Olive oil*	≥4 tbsp/day
Tree nuts and peanuts†	≥3 servings/wk
Fresh fruits	≥3 servings/day
Vegetables	≥2 servings/day
Fish (especially fatty fish), seafood	≥3 servings/wk
Legumes	≥3 servings/wk
Sofrito:	≥2 servings/wk
White meat	Instead of red meat
Wine with meals (optionally, only for habitual drinkers)	≥7 glasses/wk
Discouraged	
Soda drinks	<1 drink/day
Commercial bakery goods, sweets, and pastries	<3 servings/wk
Spread fats	<1 serving/day
Red and processed meats	<1 serving/day
Low-fat diet (control)	
Recommended	
Low-fat dairy products	≥3 servings/day
Bread, potatoes, pasta, rice	≥3 servings/day
Fresh fruits	≥3 servings/day
Vegetables	≥2 servings/wk
Lean fish and seafood	≥3 servings/wk
Discouraged	
Vegetable oils (including olive oil)	≤2 tbsp/day
Commercial bakery goods, sweets, and pastries§	≤1 serving/wk
Nuts and fried snacks	≤1 serving /wk
Red and processed fatty meats	≤1 serving/wk
Visible fat in meats and soups¶	Always remove
Fatty fish, seafood canned in oil	≤1 serving/wk
Spread fats	≤1 serving/wk
Sofrito:	≤2 servings/wk

Estruch R et al. N Engl J Med 2013. DOI: 10.1056/NEJMoa1200303



- Objective biomarkers of adherence to the supplemental foods in random samples of:
- a) urinary hydroxytyrosol, the main phenolic compound in extra-virgin olive oil, by gas chromatography—mass spectrometry
- b) the plasma proportion of alpha-linolenic acid by gas-chromatography, as a measure of adherence to walnut consumption

Male Oneen

Mediterranean Diet Reduced Cholesterol Intake Less

Table S8. Mean Baseline Values and Changes in Energy, Nutrient and Supplemental Food Intake by Study Arm.

Within group (95 % CI) changes and between-group changes for the 2 groups receiving the Mediterranean diet intervention (versus the control diet) are shown. The change is follow-up minus baseline; hence a positive sign indicates increase over time (the last available follow-up food frequency questionnaire of each participant was used).


Withir	n-group mean change	es	Between-gro	up changes	(differences vs. cont	rol)
MeDiet +	MeDiet +					
Extra-virgin Olive Oil	Nuts	Control Diet	et MeDiet + Extra-Virgin Olive Oil		MeDiet + Nuts	
(n = 2364)	(n = 2108) (n = 1941)		vs. Control Diet		vs. Control Diet	
	Mean (95% CI)		Mean (95% CI)	P value*	Mean (95% CI)	P value

Cholesterol (mg/d) -24.89 (-30.5, -19.2) -28.4 (-33.9, -22.9) -32.3 (-38.1, -26.6) 7.48 (-2.34, 17.30) 0.19 3.97 (-5.69, 13.62) 0.70

Male Oneen

Mediterranean Diet Reduces CV Events


Kaplan-Meier Estimates of the Incidence of Outcome Events in the Total Study Population.





Mediterranean Diet Clobbers Stroke Risk

Kaplan-Meier Estimates of Incidence of Stroke




Estruch R et al. N Engl J Med 2013. DOI: 10.1056/NEJMoa1200303



Mediterranean Diet did not Significantly Reduce Heart Attack Risk

Kaplan-Meier Estimates of Incidence of Heart Attack




Estruch R et al. N Engl J Med 2013. DOI: 10.1056/NEJMoa1200303




Mediterranean Diet did not Reduce Overall Mortality

Kaplan-Meier Estimates of the Incidence of Outcome Events in the Total Study Population.





Subgroup Analyses.





- Diet had significant benefit in older, overweight, hypertensive, dyslipidemic, metabolic syndrome type males without a positive famhx of CVD, if they had higher adherence to the diet
- The decreased CV risk was driven by reduction in stroke; not heart attack

Estruch R et al. N Engl J Med 2013. DOI: 10.1056/NEJMoa1200303



Findings are consistent with smaller trials assessing effects of Mediterranean diet, olive oil and nuts on risk factors, such as BP and markers of oxidation, inflammation and endothelial dysfunction.

Why huge reduction in stroke in 'nut' arm??



Walnuts improve endothelial function in hypercholesterolemic subjects

Variable	Baseline	Control diet	Walnut diet	р
Endothelium- dependent vasodilation (%)	3.4	3.6	5.9	0.043
Intracellular adhesion molecule-1 (µmol/L)	355	370	343	>0.1
Vascular cell adhesion molecule-1 (µmol/L)	474	465	378	0.045

18 subjects; cross-over study; four week periods

Mediterranean diet vs. medit. diet with walnuts substituted for olive oil, olives, avocados

Ros E et al. Circulation 2004 Mar 22; 109:1609-14.



Pistachios reduce BP

28 adults with dyslipidemia completed a randomized, crossover, controlled-feeding study. All meals provided and calories controlled. On diet for 4 weeks.

Reductions in SBP after diet containing 1 serving/day: 6.2 ±1.9 mmHg 2 servings/day: 5.0 ±1.9

in DBP after diet containing 1 serving/day: 1.7 ±1.0 2 servings/day: 2.3 ±1.0

West S.G, Gebaurer S.Kl, et al. Hypertension. May 3, 2012; 60:58-63.



BD Method Thoughts

- Supports inflammation as causal of ASVD
- Supports importance of BP in stroke reduction
- Supports a very palatable diet can be beneficial
- The Mediterranean diet alone is not a panacea and did not reduce mortality risk
- Would anticipate even better results with some caloric restriction and monitoring of oxidation and inflammation



Hot Topics







HPS2-THRIVE: Randomized placebocontrolled trial of ER niacin and laropiprant in 25,673 patients with pre-existing cardiovascular disease.

Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group





HPS2-THRIVE: Eligibility

Men and women

Aged 50-80 years

Prior history of: myocardial infarction;

ischaemic stroke or TIA;

peripheral arterial disease; or

diabetes with other CHD

No contra-indication to study treatments

No significant liver, kidney or muscle disease







HPS2-THRIVE: Active pre-randomization run-in

Screened (51,698)



LDL lowering phase (36,059)

Standardise background LDL-lowering therapy with simvastatin 40 mg (+/- ezetimibe) daily (to total cholesterol target of 135 mg/dL)



Active ER niacin plus laropiprant (38,369)

Test compliance with ER niacin 2 grams plus laropiprant 40 mg (ERN/LRPT) daily for 1 month



Randomization (25,673)

ER niacin 2g plus laropiprant 40 mg daily vs. matching placebo tablets



Characteristics of randomized participants

% or mean (SD)	ERN/LRPT (12,838)	Placebo (12,835)	All
Men	83%	83%	21,229 (83%)
Age (years)	64.9	64.9	64.9 (7.5)
Prior disease			
Coronary	78%	78%	20,137 (78%)
Cerebrovascular	32%	32%	8170 (32%)
Peripheral arterial	13%	12%	3214 (13%)
Diabetes	32%	32%	8299 (32%)





Baseline LIPIDS on statin-based therapy

	Mean (SD) baseline		
	mg/dL	mmol/L	
Total cholesterol	128 (22)	3.32 (0.57)	
Direct-LDL	63 (17)	1.64 (0.44)	
HDL	44 (11)	1.14 (0.29)	
Triglycerides*	125 (74)	1.43 (0.84)	

^{*64%} fasted for >8 hours





Effects of ER niacin/laropiprant on lipids


Year of FU	LDL-C (mg/dL)	HDL-C (mg/dL)	Triglycerides (mg/dL)
1	-12	6	-35
4	-7	6	-31
STUDY AVERAGE	-10	6	-33

No 'niacin creep' observed
The change in the TC/HDL ratio would be minimal going from 2.9 to ~ 2.5
Going from optimal to optimal should not improve risk significantly





Effect of ERN/LRPT on MAJOR VASCULAR EVENTS



Effect of ERN/LRPT on MAJOR VASCULAR EVENTS

	Randomized	allocation			
Event	ERN/LRPT	Placebo	Risk ratio & 95% C	l e	p
	(12838)	(12835)			
			<u>_</u>	2 22 (2 22 . 27)	
Non-fatal MI	402 (3.1%)	431 (3.4%)		0.93 (0.82-1.07)	0.33
Coronary death	302 (2.4%)	291 (2.3%)		1.04 (0.89-1.22)	0.63
Major coronary event	668 (5.2%)	694 (5.4%)		0.96 (0.87-1.07)	0.51
Ischaemic stroke	389 (3.0%)	415 (3.2%)		0.94 (0.82-1.08)	0.37
Haemorrhagic stroke	114 (0.9%)	89 (0.7%)		1.28 (0.97-1.69)	0.08
Any stroke	498 (3.9%)	499 (3.9%)		1.00 (0.88-1.13)	0.56
Coronary revasc	591 (4.6%)	664 (5.2%)		0.89 (0.80-0.99)	0.04
Non-coronary revasc	236 (1.8%)	258 (2.0%)		0.92 (0.77-1.09)	0.33
Any revascularization	807 (6.3%)	897 (7.0%)		0.90 (0.82-0.99)	0.03
Major vascular event	1696 (13.2%) 1	1758 (13.7%)		0.96 (0.90-1.03)	0.29
			0.8 1.0 1.2	2	



Certainly no signal of CV ERN/LRPT better harm other than hemorrhagic stroke

Placebo better 🕼





This trial was not an ER niacin trial: there was an intruder!!





BD Method Concern with new ER niacin (Cordaptive): 2008!

- Uses an investigational PGD2 receptor antagonist (laropriprant) to reduce flushing (blocks DP1 receptor)
- PDG2 leads to 15-deoxyprostaglandin J2 which is potent ligand of PPAR-gamma*
- Potential CV benefits of stimulating PPAR-gamma include: reduction in MMP-9; MCP; HsCRP; PAI-1; fibrinogen; tumor necrosis factor alpha; ADMA^

*Journal of Clinical Lipidology 8/2007 Vol 1, No. 4:248-255

^ Bale/Doneen Method 3/7/2008



Laropiprant: Numerous Potential Adverse Effects from Blocking PD1

- Evidence supports DP1 receptor mediated effects of PGD2 are anti-inflammatory
- In asthma, signaling through DP1 appears antiinflammatory
- DP1 signaling in bronchial smooth muscle causes bronchodilation



Laropiprant: Numerous Potential Adverse Effects from Blocking PD1

- PGD2 enhances sleep and this appears to be at least partially a DP1 mediated effect
- DP1 receptor mediates the erectile response in humans

 DP1 mediated-effect enhancing insulin sensitivity has not been ruled out



Laropiprant: no reason to believe it will block niacin's adverse skin reactions

- Co-administration of niacin and DP1 antagonists assumed to be appropriate step to enhance tolerability.
- Evidence suggests the dermal effects of niacin are much more complex.
- A number of cell types are involved in the adverse effects of niacin on the skin: there is certainly evidence for a role for macrophages and platelets.



Laropiprant Might Cause more Bleeding

- Laropiprant has been shown to be an antagonist of the TP receptor.
- It is the TP receptor that mediates the powerful activation driven by thromboxane A2
- It may be that laropiprant acting in this capacity would inhibit platelet activation



Laropiprant Might Cause more Infection by Increasing Levels of PGD2

- Increase in PGD2 in mice led to diminished respiratory dendritic cell migration resulting in defects in virus-specific T-cell responses in vivo.
- Administration of PGD2 antagonist reversed this defect resulting in migration of dendritic cells with enhancement of T-cell antivirus response with increased clearance and survival
- These data suggest that similar to allergic airway disease PGD2 may have immunosuppressive effects in viral infections.

```
Myungsoo Joo, M., et. al.
Mediators Inflamm. 2012; 2012: 503128.
Published online 2012 June 25. doi: 10.1155/2012/503128
```



Stimulation of DP1 Receptor is Neuroprotective

- Ischemia injury was produced by a 90-min occlusion of the right middle cerebral artery followed by a 4-day reperfusion.
- Infarct size was 49.0 ± 11.0% larger in DP1-/- mice (n = 11; P < 0.01) than in WT mice
- Corticostriatal neuronal cultures were exposed to DP1selective agonist; provided dose-dependent protection against excitotoxicity induced by glutamate.
- DP1 receptor is neuroprotective in both in vivo and in vitro paradigms

Saleem, S., et. al. *Eur J Neurosci*. 2007 July ; 26(1): 73–78




Laropiprant May Effect Levels of 15 deoxyprostaglandin J2 (15 d-PGJ2)

- 15 deoxy-PGJ2 is produced in sufficient quantities by PGD2 to activate PPARγ
- Many of the anti-inflammatory effects of niacin may well be mediated by this receptor
- If PGD2 cannot bind to DP1, various metabolite levels could be affected




Could Blocking DP1 Result in Greater 15d-PGD2 and Less 15d-PGJ2 ???





Blocking DP1 May not be a Good Idea!



J.U. Scher, M.H. Pillinger / Clinical Immunology 114 (2005) 100–109

15 d-PGJ2 Questions Remain

- 15d-PGJ2 is an endogenous PPARg ligand as well as a direct inhibitor of several other signal transduction pathways.
- The consequences of these activities are complex & likely to play a role in the prevention and/or resolution of inflammation.
- Many questions remain, including the possible existence of a specific 15d-PGJ2 membrane receptor.
- Additional research will be needed to elucidate both the biology and importance of 15d-PGJ2

J.U. Scher, M.H. Pillinger / Clinical Immunology 114 (2005) 100-109



Other Potential Benefits from PPAR gamma which would be lost if laropiprant decreases this stimulation



HDL Ability to Perform Reverse Cholesterol Transport Enhanced with Pioglitazone

39 met. synd. pts; 16 pio for 12 wks. & 23 placebo;
 pio 30mg 6wks. then increased to 45mg

Rx	N	% change efflux	95% CI	p vs baseline	P vs placebo
Pio	16	11.3	1.8-20.8	0.02	0.04
Placebo	23	0.0	-6.2-6.1	0.99	

Increased HDL-C 14%: no significant association with change in efflux capacity (r = 0.22; P = 0.18)

Khera, A. V., M.D., et. al. N Engl J Med 1/2011;364:127-35.



Pioglitazone Decreases ADMA and Improves Endothelial Function

- 17 non-DM subjects with CAD; mean age 58; rx pio 30mg X 12 wks. followed 12 wks. without rx
- Urine ADMA levels decreased with rx (30%), 1.27
 ± 0.5 µmol/ml to 0.97 ± 0.3, p = 0.017; returned to the initial values after the wash-out period
- Endothelium-dependent vasodilation improved significantly with the treatment from 4.4 ± 3.9 to 8.4 ± 4.1%, a relative increase of 91%; p<0.001

Staniloae, C., et. al. *Cardiology* 2007;108:164-169



Pioglitazone Lowers MACR

- 63 DM with BP on RAAS rx & elevated MACR; 32- pio 15-30mg/d or 31-metformin 500-750mg/d; X one year
- Similar glycemic and BP changes
- MACR decreased 8.3% in pio group and increased 4.2% in metformin group p=0.01



Pioglitazone Favors Anti-inflammatory Macrophages

- Inflammation initiates recruitment of neutrophils and monocytes to the damaged tissue.
- This process can rapidly terminated via anti-inflammatory cytokines.
- An imbalance of inflammation initiation and arrest results in chronic inflammatory diseases (atherosclerosis).
- Macrophages in atherosclerotic plaques are heterogeneous:
 - 1) proinflammatory "classical" M1
 - 2) anti-inflammatory "alternative" M2
- PPAR gamma (Pioglitazone) favors M2 polarization

Mandy Bloch, et. al., Circulation Research. 2/2012;110: 394-405



Pioglitazone Slashes Risk of Diabetes Conversion 72%

- 602 patients with IGT (FG 95-125mg/dL & or OGTT 140-199 mg/dL); Median follow-up 2.4 yrs.
- Randomized pioglitazone 30 -45 mg or placebo
- HR for DM -0.28; p<0.00</p>

DeFronzo RA, et al. N Engl J Med 3/24/2011; 12:1104-1115




If laropiprant causes defects in virus-specific T-cell responses, decreases bronchial dilitation, increases inflammation, inhibits platelet aggregation, causes more stimulation of DP2 receptor and reduces the stimulation of PPAR gamma, what side effects might you expect??

- Increased infection especially respiratory
- Increases GI and cerebral bleeding
- Increased peptic ulcer
- More hyperglycemia in diabetics
- Increased risk of new onset diabetes
- Less CV benefit



Effect of ERN/LRPT on SERIOUS adverse events (median follow-up 3.9 years)







Effect of ERN/LRPT on glucose related SAEs

Serious adverse event	ERN/LRP	Γ Placebo	Risk ratio (95% CI)			
Participants with diabetes at randomization (n= 8299)						
Minor hyperglycaemic problem	8.7%	5.8%	1.55 (1.32-1.82)			
Major hyperglycaemic problem	1.0%	0.3%	3.09 (1.81-5.27)			
Hypoglycaemia	1.1%	0.7%	1.50 (0.96-2.35)			
Other diabetic complication	1.1%	1.2%	0.93 (0.62-1.40)			
Any diabetic complication	460 (11.1%)	311 (7.5%)	1.55 (1.34-1.78)			

Participants without diabetes at randomization (n= 17,374)

New-onset diabetes mellitus

792

632

1.27 (1.14-1.41)

(9.1%)

(7.3%)





AIM-HIGH (ER niacin without laro) & Hyperglycemia

- 1,696 placebo; 1,718 ER niacin; 85% (83%*) men; 34% (32%*) DM; follow-up ~ 3 years (3.9 yrs*)
- "Adverse effects were rare and included liver-function abnormalities (0.5% in the placebo group and 0.8% in the niacin group), muscle symptoms or myopathy (0.3% of the patients overall), and rhabdomyolysis (1 patient in the placebo group and 4 in the niacin group)."
- New onset DM not even mentioned!!!!

The AIM-HIGH Investigators. N Engl J Med 12/15/2011. 365;24:2255-2267 * HPS-THRIVE

Effect of ERN/LRPT on infection and bleeding

Serious Adverse Event	ERN/LRPT (12,838)	Placebo (12,835)	Risk ratio (95% CI)
Infection			
Lower respiratory	4.3%	3.7%	1.17 (1.03-1.32)
Urinary tract	0.9%	0.8%	1.07 (0.82-1.39)
Abdominal/gastrointestinal	0.6%	0.5%	1.26 (0.91-1.75)
Skin	0.5%	0.3%	1.66 (1.14-2.43)
Other	2.4%	1.7%	1.38 (1.16-1.63)
Any infection SAE	1031 (8.0%)	853 (6.6%)	1.22 (1.12-1.34)
Bleeding			
Gastrointestinal	0.8%	0.6%	1.53 (1.14-2.05)
Intracranial	1.1%	0.9%	1.17 (0.92-1.50)
Other	0.6%	0.4%	1.66 (1.18-2.34)
Any bleeding SAE	326 (2.5%)	238 (1.9%)	1.38 (1.17-1.62)



Study stopped early due to SAEs; it was not due to CV Risk!



HPS2-THRIVE: SUMMARY









HPS2-THRIVE: SUMMARY

- Significant excesses of serious adverse events (SAEs) due to known and unrecognised side-effects of niacin. Over 4 years, ER niacin/laropiprant caused SAEs in ~30 patients per 1000
- No significant benefit of ER niacin/laropiprant on the primary outcome of major vascular events when added to effective statin-based LDL-lowering therapy
- No clear evidence of differences in efficacy or safety in different types of patient (except for an excess of statinrelated myopathy in Chinese patients)
- Findings are consistent with previous niacin trials. ??? The role of ER niacin for the treatment and prevention of cardiovascular disease needs to be reconsidered





BD Method HPS-THRIVE Conclusions

- Study supports optimal TC/HDL <3.0</p>
- Study supports inflammation as causal and simply taking care of lipids as inadequate to halt the disease in many individuals (too bad no biomarkers available!)
- ER niacin plus laropiprant is not the same as ER niacin!!
- Conclusions about using ER niacin cannot be derived from this trial !!!
- It probably is not a good idea to block DP1: the 'flush' is probably good!



BD AIM HIGH Conclusions

- Study does not affect our use of niacin
- Continue to prescribe niacin
- Good candidates:
 - patients who are statin intolerant
 patients who are not at TC/HDL goal
 patients with the lipo (a) issue
 patients with IR dyslipidemia
 patients with persistent arterial inflammation

Case



Kindly submitted by Dr. Linda Groene



- "young" 75 yo female
- Meds: crestor 10mg; niacin 500mg bid; losartan (intolerant of ACEI); atenolol; fish oil; ASA low dose; vit. D; folic acid
- Exercise daily; low fat diet
- Quit smoking seven yrs ago
- Disease: ABI wnl; abd US '08- wnl; +CAD on angio 3/11 with 30-40% stenotic plaque mid-RCA; + CIMT in 1/10 with mean CCA 1.37 mm; 1/13 with mean CCA 1.41 mm + right CCA-2.1H, bulb-2.3H, ICCA-2.0E; left CCA-3.6H, bulb-2.7mmH, ICCA-3.8H (worse now than in 2010 ??)
- TC-183, TG-67, HDL-68, LDL-73; TC/HDL=2.7; lipo (a)- 20
- F2 isoprostane-0.4; MACR-22.2; hsCRP-1.1; LpPLA2-314; MPO-282 in 8/12

What to do next?? Guess saliva test is in order.



Disease: we do not know that she is worse. The margin of error in the best of hands for the mean CCA thickness is + or – 0.06mm. Therefore, going from 1.37 mm to 1.41 mm is not any significant change. Unfortunately, the first CIMT did not contain any plaque data. Her current CIMT shows significant plaque. Fortunately, there is some echogenicity in all of the plaques which indicates some stabilization of the disease. Next year's CIMT will be interesting in terms of the plaque and you would hope some of the H goes to E.



 Fire: assume she is currently high risk for a CV event with evidence of endothelial and intimal inflammation.

Roots:

IR – any info on OGTT?

Sleep – any issues?

Psychosocial -pt claims no issue

Oral health – absolutely salivary testing and referral ASAP to an oral medicine specialist

Optimal: BP?

Genetics: ?; will want salivary IL-1 beta



Management:

consider increasing niacin or crestor if IR, consider low dose pioglitazone why atenolol? why folic acid?



Upcoming Presentations







Upcoming Presentations

- 4/13/2013 Brad (Amy running Boston Marathon on 15th ! ☺)-21st Annual World Congress on Anti-aging and Aesthetic Medicine; Orlando, FL
- 4/24/2013 Keynote Speakers Delta Dental Executive National Program; St. Louis, MO
- 4/27/2013 BD Method Inflammation 5 hr. CME sponsored by CHL;
 Denver, CO
- 5/17-18/2013 BD Method Preceptorship; 17 hr. CME; Washington, DC
- 8/11/2013 Brad (Amy enjoying her lake place with family!☺) Florida Endocrine Society "2013 Post Graduate Update"; Orlando, FL
- 9/13-14/2013 BD Method Preceptorship; 17 hr. CME; Lubbock, TX



Open for Discussion

